Buy Laurus Labs; target of Rs 400: ICICI Direct

ICICI Direct's research report on Laurus Labs

Laurus Labs operates in the segment of generic APIs & FDFs (formulations), custom synthesis and biotechnology. Major focus in APIs is on ARV, oncology and other APIs. It owns 11 manufacturing units (six FDA approved sites) with 74 DMFs, 32 ANDAs filed (15 Para IV, 11 first to file) and 192 patents granted • Laurus acquired Richore Life Sciences to diversify in the area of recombinant animal origin free products, enzymes as well as building biologics custom synthesis.

Outlook

We continue to remain positive and retain our BUY rating on the stock amid incremental contribution from custom synthesis with visible order- book. Valued at Rs 400 i.e. 18x P/E on FY25E EPS of Rs 22.3.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Laurus Labs - 01 -01-2023 - ic